---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-097804"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:37:44.543801+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals raises $1.2M via private placement of preferred shares and warrants at $0.40

## Summary
- Issued 3M shares of Series A Preferred Stock and 3M warrants, each at $0.40, raising ~$1.2M from existing investors.
- Preferred shares convert to common stock after 6 months or earlier if stock price reaches $1.20 per share.
- Warrants exercisable at $0.40 per share for 5 years, also early conversion if $1.20 trigger met.
- Proceeds to fund development of NRX-101 for Suicidal Bipolar Depression and Chronic Pain, plus general corporate purposes.
- Certificate of Designation filed with Delaware authorizing up to 12M shares of Series A Preferred.

## SEC filing metadata
- accession: 0001104659-23-097804
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/tm2317653d12_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-097804
- JSON: https://secwatch.observer/filing/0001104659-23-097804.json
- Plain text: https://secwatch.observer/filing/0001104659-23-097804.txt

## Key facts
- Governance Changes
  NRX Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock, establishing preferences, rights, and limitations (effective 2023-08-30).
  - Change: charter amendment
  - Effective: 2023-08-30
  source text: On August 30, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Delaware Secretary of State (the "Certificate of Designation") authorizing up to 12,000,000 shares of Series A Convertible Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers signatory thereto (the "Investors") valued at approximately $1.2 million (effective 2023-08-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers signatory thereto (the "Investors")
  - Value: approximately $1.2 million
  - Effective: 2023-08-28
  source text: On August 28, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers signatory thereto (the "Investors"), pursuant to which the Company issued 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the " Series A Preferred Stock "), and one (1) investor warrant (each an "Investor Warrant") for every share of Series A Convertible Preferred Stock issued.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923097804/0001104659-23-097804-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.